imipramine has been researched along with Metabolic Syndrome in 2 studies
Imipramine: The prototypical tricyclic antidepressant. It has been used in major depression, dysthymia, bipolar depression, attention-deficit disorders, agoraphobia, and panic disorders. It has less sedative effect than some other members of this therapeutic group.
imipramine : A dibenzoazepine that is 5H-dibenzo[b,f]azepine substituted by a 3-(dimethylamino)propyl group at the nitrogen atom.
Metabolic Syndrome: A cluster of symptoms that are risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components of metabolic syndrome include ABDOMINAL OBESITY; atherogenic DYSLIPIDEMIA; HYPERTENSION; HYPERGLYCEMIA; INSULIN RESISTANCE; a proinflammatory state; and a prothrombotic (THROMBOSIS) state.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study has shown that imipramine as an inhibitor of aSMase abolishes the synergy between MetS and periodontitis on alveolar bone loss in animal model and inhibits pro-inflammatory and pro-osteoclastogenic gene expression in macrophages in vitro." | 8.12 | Inhibition of acid sphingomyelinase by imipramine abolishes the synergy between metabolic syndrome and periodontitis on alveolar bone loss. ( Huang, Y; Kirkwood, CL; Kirkwood, KL; Li, Y; Lopes-Virella, MF; Lu, Z; Zhang, L, 2022) |
| "This study has shown that imipramine as an inhibitor of aSMase abolishes the synergy between MetS and periodontitis on alveolar bone loss in animal model and inhibits pro-inflammatory and pro-osteoclastogenic gene expression in macrophages in vitro." | 4.12 | Inhibition of acid sphingomyelinase by imipramine abolishes the synergy between metabolic syndrome and periodontitis on alveolar bone loss. ( Huang, Y; Kirkwood, CL; Kirkwood, KL; Li, Y; Lopes-Virella, MF; Lu, Z; Zhang, L, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, Y | 2 |
| Lu, Z | 2 |
| Zhang, L | 1 |
| Kirkwood, CL | 1 |
| Kirkwood, KL | 1 |
| Lopes-Virella, MF | 1 |
| Huang, Y | 2 |
| Chowdhury, N | 1 |
| Yu, H | 1 |
| Syn, WK | 1 |
| Lopes-Virella, M | 1 |
| Yilmaz, Ö | 1 |
2 other studies available for imipramine and Metabolic Syndrome
| Article | Year |
|---|---|
Inhibition of acid sphingomyelinase by imipramine abolishes the synergy between metabolic syndrome and periodontitis on alveolar bone loss.
Topics: Alveolar Bone Loss; Animals; Disease Models, Animal; Imipramine; Lipopolysaccharides; Metabolic Synd | 2022 |
The Presence of Periodontitis Exacerbates Non-Alcoholic Fatty Liver Disease via Sphingolipid Metabolism-Associated Insulin Resistance and Hepatic Inflammation in Mice with Metabolic Syndrome.
Topics: Animals; Ceramides; Diet, High-Fat; Imipramine; Inflammation; Insulin Resistance; Lipopolysaccharide | 2023 |